Related Topics
     

    Relling: News Releases & Feature Stories

     
    01/11/2013
    Prescribing Gets Personal

    Scientists at St. Jude Children's Research Hospital are mining the genetic code to better match patients and medications now and in the future.

     
     
    01/12/2012
    Writing the Next Chapter

    For many years, St. Jude researchers have been investigating the connection between genetics and pediatric cancer. Those approaches continue to have dramatic implications for clinical care.

     
     
    05/17/2011
    Things are looking up for teens with ALL

    St. Jude boosts cure rates for older teens with acute lymphoblastic leukemia.

     
     
    02/07/2011
    Native American ancestry linked to greater risk of relapse in young leukemia patients

    New research from St. Jude Children’s Research Hospital and the Children’s Oncology Group ties the genetic variation characteristic of Native American ancestry to higher odds cancer will return and highlights a strategy to ease the racial disparities in survival.

     
     
    12/20/2010
    Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients

    Research led by St. Jude Children’s Research Hospital investigators will likely impact how acute lymphoblastic leukemia is treated in young adults and shows older adolescent age does not dictate worse outcomes against the most common childhood cancer

     
     
    09/07/2010
    St. Jude researcher receives grant to focus on cancer pharmacogenomics in children

    With its new expansion of the Pharmacogenomics Research Network (PGRN), the National Institutes of Health (NIH) awarded St. Jude Children’s Research Hospital a prestigious grant to focus on anticancer agent research in children. The five-year, $8.6 million grant is titled “PAAR4Kids—Pharmacogenomics of Anticancer Agents Research in Children.”

     
     
    10/12/2009
    Two St. Jude faculty elected to Institute of Medicine

    Michael Kastan, MD, PhD, and Mary Relling, PharmD, of St. Jude Children’s Research Hospital, have been elected to the Institute of Medicine (IOM), a prestigious branch of the National Academy of Sciences.

     
     
    08/17/2009
    Inherited risk factors increase odds of developing childhood acute lymphoblastic leukemia

    Scientists at St. Jude Children’s Research Hospital have identified inherited variations in two genes that account for 37 percent of childhood acute lymphoblastic leukemia (ALL), including a gene that may help predict drug response.

     
     
    08/10/2009
    The big picture

    How can we design more effective chemotherapy for childhood leukemia? St. Jude researchers look at the big picture—and find intriguing answers.

     
     
    06/24/2009
    Acute lymphoblastic leukemia, the most common childhood cancer, is curable without preventive cranial radiation

    Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully personalized chemotherapy regimen without cranial radiation, investigators at St. Jude Children's Research Hospital have found. Such radiation of the brain was once a standard ALL treatment to prevent recurrence of the leukemia in the central nervous system (CNS).

     
     
    04/14/2009
    St. Jude Acute Lymphoblastic Leukemia Team recognized with prestigious science award

    Scientists at St. Jude Children’s Research Hospital who represent the interdisciplinary team studying acute lymphoblastic leukemia (ALL) have been recognized by the American Association for Cancer Research (AACR) with the AACR Team Science Award.

     
     
    02/03/2009
    St. Jude finds more than 100 gene variations linked with response to leukemia treatment

    Scan of thousands of inherited genetic changes reveal specific variations linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute lymphoblastic leukemia.

     
     
    01/27/2009
    St. Jude finds more than 100 gene variations linked with response to leukemia treatment (news release)

    Scan of thousands of inherited genetic changes reveal specific variations linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute lymphoblastic leukemia

     
     
    05/11/2007
    Inherited genes linked to toxicity of leukemia therapy

    Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.

     
     
    03/02/2005
    Both inherited traits and tumor mutations affect response to treatment of leukemia

    The outcome of chemotherapy treatment for acute lymphoblastic leukemia (ALL) depends not only on the acquired genetic make-up of the leukemic cells, but on genes that children inherit from their parents.

     
     
    06/02/2004
    Pharmacogenomics: Pioneering the Delivery of Individualized Medicine

    Pharmacogenomics, is a cutting-edge technology for studying how populations of specific genes control an individual's response to drug therapy.